Soricimed Biopharma Inc. Announces U.S. Trial Site for Phase I Clinical Trial of New Cancer Drug, SOR-C13


Toronto, ON, Canada, May 23, 2013 — , a private stage company developing novel therapeutics and diagnostics, is pleased to announce that it has added a third and first site, to its I clinical , with the first patient beginning treatment this week with anti-cancer agent SOR-C13 at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Soricimed’s Phase I trial is a multicenter, open-label, dose escalation study that is taking place at cancer centres in both the United States and Canada. The trial is designed to assess safety and tolerability in patients with advanced cancer tumors, with a weighting on ovarian cancers.  The trial will also assess pharmacokinetics, biomarkers and initial evidence for efficacy.
SOR-C13 is a targeted peptide derived from the venom of the northern short-tailed shrew.  It works by inhibiting a non-voltage gated calcium channel found in epithelial cancers such as ovarian, breast, prostate and others.  Pre-clinical studies have shown that SOR-C13 induces apoptosis (cell death), inhibits cell proliferation and reduces tumor volume while minimizing side effects associated with typical chemotherapy
“Unlike chemotherapy, Soricimed’s cancer treatment is highly targeted – affecting only cancer cells that over-produce this strange ion channel,” said Jack Stewart, Chairman and Chief Scientific Officer of Soricimed Biopharma.  “Healthy cells are not affected. It’s also derived from a naturally occurring peptide that, when broken down, produces amino acids that are normally used by the body. As a result, and this is key, there have been virtually no side effects demonstrated in our pre-clinical studies.”
“We are thrilled to be partnering with The University of Texas MD Anderson Cancer Center, a premier cancer center in the world,” stated Paul Gunn, President and CEO, Soricimed Biopharma.  “We share a common…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS